Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.32 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.31 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.30 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12573766 | 1.00 | CXCR1 (0.33) | CXCR1CXCR2TP53ALKCTNNB1 | |
| SCHEMBL15280006 | 0.94 | CXCR1 (0.33) | CXCR1CXCR2TP53ALKCTNNB1 | |
| SCHEMBL12573763 | 0.94 | CXCR1 (0.33) | CXCR1CXCR2TP53ALKCTNNB1 | |
| SCHEMBL1333834 | 0.94 | ALK (0.33) | CXCR1CXCR2TP53ALKCTNNB1 | |
| SCHEMBL12573772 | 0.94 | ALK (0.33) | CXCR1CXCR2TP53ALKCTNNB1 | |
| SCHEMBL12573736 | 0.94 | ALK (0.33) | CXCR1CXCR2TP53ALKCTNNB1 | |
| SCHEMBL3697608 | 0.91 | TRPA1 (0.32) | CXCR1CXCR2TP53ALKCTNNB1 | |
| SCHEMBL1333767 | 0.90 | CTNNB1 (0.32) | CTNNB1TCF7L2MAPTP2RY14TRPA1 | |
| SCHEMBL12634202 | 0.90 | CTNNB1 (0.32) | CTNNB1TCF7L2MAPTP2RY14TRPA1 | |
| SCHEMBL29910223 | 0.90 | PLG (0.35) | MEN1KMT2ARAB9AP2RY14DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2652552-B9 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL INC (US) | 2016-02-17 | — | — | EP | disclosed |
| EP-2652552-B1 | PHOTOCHROMIC COMPOUNDS AND COMPOSITIONS | TRANSITIONS OPTICAL INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-8545984-B2 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| US-20110129678-A1 | Photochromic compounds and compositions | TRANSITIONS OPTICAL, INC. (US) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110129678-A1 | Photochromic compounds and compositions | CRY2, CRY1, PPOX | CXCR1 2866/4885CXCR2 1904/4885TP53 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.